Monte Rosa Therapeutics is rated a risky Buy, as $580 million cash leaves its pipeline worth about $215 million, with MRT-6160 and MRT-2359 catalysts.
The blended fair value estimate for Monte Rosa Therapeutics has shifted from US$28.00 to US$25.38, reflecting updated assumptions in the latest analyst work. Recent Street commentary links this adjustment to a mix of optimism around MRT-8102 and NEK7 progress, along with caution on execution risk and current valuation, which has led some analysts to trim price targets. Read on to see how these moving pieces fit together and how to track the evolving Monte Rosa Therapeutics story from...
NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1, a Phase 2 study of MRT-8102 in patients with gout, is expected to initiate in Q4 2026, with initial data expected in H2 2027 Poster presentation on November 9, 2026, at 10:30 a.m. ET BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology
BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Guggenheim's 3rd Annual Healthcare Innovation Conference (Boston, MA) – fireside chat, November 9, 2026, at 8:00 a.m. ETUBS Global Biopharma Conference 2026 (London, UK) – fireside chat, November 16, 2026, at 12:00 p.m. G
Monte Rosa Therapeutics (NASDAQ:GLUE) reported results from GFORCE-1, a Phase I study of its NEK7-directed molecular glue degrader MRT-8102 in participants with elevated cardiovascular risk. The company said the four-week dosing study showed sustained degradation of NEK7, reductions in inflammatory
2026-10-05. The following slide deck was published by Monte Rosa Therapeutics, Inc.
Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.
Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to five newly hired non-executive employees as a material inducement to commencing their employment with the Company. The employees received, in the aggregate, non-qualified stock options to purchase 86,725 shares of Monte Rosa Therapeutics common stock,
Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normalized multiple atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers of local plaque inflammation, thrombosis, and systemic inflammation Robust and sustained NEK7 degradation observed across 5 mg, 20 mg, and 40 mg once-daily dose levels, with similar biomarker reductions at all three doses
Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose
Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102
On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a […]
Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.
Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE)
Monte Rosa made a strategic move to partner with Novartis, which now has the responsibility for Phase 2 clinical development. Read why GLUE stock is a buy.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 10, 2026, at 12:45 p.m. ETMorgan Stanley 24th Annual Global Healthc
Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safety Updated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide in patients with advanced CRPC expected by end of year BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that the first patient has been dosed
This is the newest page. Registered accounts read further back.